Could a simple shot replace hospital stays for myeloma patients?

NCT ID NCT07637578

Recruiting now Disease control Sponsor: SCRI Development Innovations, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of another medicine to lower the risk of a common side effect called cytokine release syndrome. The main goal is to see how many patients experience this side effect during the first treatment cycle.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA MULTIPLE MYELOMA (MM) MULTIPLE MYELOMA IN RELAPSE MULTIPLE MYELOMA REFRACTORY

Contacts and locations

Locations

Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Maryland Oncology Hematology
RECRUITING

Columbia, Maryland, 21044, United States
Rocky Mountain Cancer Center
RECRUITING

Denver, Colorado, 80218, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Willamette Valley Cancer Institute and Research Center
RECRUITING

Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.